Physician

Alexander Bangiev, M.D.

According to 2025 Medicare claims, Alexander Bangiev, M.D. (NPI: 1689636375) practices nephrology in the New York-Jersey City-White Plains, NY-NJ market, with the plurality of this provider's patient population coming from Queens, NY. This provider's primary affiliated billing organization is NEPHROLOGY MEDICAL CARE PLLC (NPI: 1306222526) and primary practice location at 11355-5045.

Bangiev's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 599 traditional Medicare patients, billed 3,660 HCPCS/CPT codes, and received $356,659 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,664 prescription claims across 399 beneficiaries totaling $947,198 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 289 claims. Open Payments data shows 52 records totaling $1,034. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $480,505 and ending at $947,198. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $0 to $1,673.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	585	4,095	$395,210
2016	552	4,257	$367,444
2017	522	3,627	$305,764
2018	624	4,089	$347,909
2019	633	4,058	$369,810
2020	518	3,094	$307,279
2021	598	3,974	$411,654
2022	582	3,474	$370,504
2023	568	3,464	$374,135
2024	599	3,660	$356,659

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	215	2,518	$480,505
2016	216	2,646	$910,713
2017	243	2,542	$708,400
2018	272	2,979	$595,226
2019	290	2,988	$372,097
2020	264	2,475	$323,799
2021	289	2,667	$257,148
2022	319	2,865	$393,663
2023	353	3,572	$625,042
2024	399	3,664	$947,198

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	70	$4,342
2019	N/R	156	$5,837
2020	N/R	136	$4,850
2021	N/R	175	$8,994
2022	N/R	189	$6,434
2023	N/R	363	$29,972
2024	N/R	289	$5,042

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	206	372	$106
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	142	169	$105
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	116	354	$96
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	248	1,575	$64
36415	Insertion of needle into vein for collection of blood sample	169	305	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	272	10,920	$196,366
Xphozah	Tenapanor Hcl	46	1,368	$131,964
Procrit	Epoetin Alfa	33	1,228	$54,515
Velphoro	Sucroferric Oxyhydroxide	21	690	$47,520
Lokelma	Sodium Zirconium Cyclosilicate	62	2,170	$41,915

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	13	$1,203
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	65	$1,078
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	86	$1,020
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	54	$922
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	54	$807

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	52	$1,034	GlaxoSmithKline, LLC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Alexander Bangiev, M.D.?

Tedicare shows public-source Medicare data for Alexander Bangiev, M.D. (NPI 1689636375), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alexander Bangiev, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Alexander Bangiev, M.D.?

Alexander Bangiev, M.D. is linked to NEPHROLOGY MEDICAL CARE PLLC (billing NPI 1306222526) in the available physician profile data.

Does Alexander Bangiev, M.D. have Open Payments data?

Alexander Bangiev, M.D. has 52 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.